Literature DB >> 25480501

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.

Ingrid M Ariës1, Rosanna E van den Dungen1, Marco J Koudijs2, Edwin Cuppen2, Emile Voest2, Jan J Molenaar3, Huib N Caron3, Rob Pieters4, Monique L den Boer5.   

Abstract

Entities:  

Keywords:  RAS; clonal mutations; pediatric acute lymphoblastic leukemia; prednisolone resistance

Mesh：

Substances：

Year:  2014        PMID： 25480501      PMCID： PMC4380734          DOI： 10.3324/haematol.2014.112995

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Authors:  Marian Case; Elizabeth Matheson; Lynne Minto; Rosline Hassan; Christine J Harrison; Nick Bown; Simon Bailey; Josef Vormoor; Andrew G Hall; Julie A E Irving
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

2.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

3.  Binding of the glucocorticoid and estrogen-receptors to the human h-ras oncogene sequences.

Authors:  G Zachos; V Zoumpourlis; C Sekeris; D Spandidos
Journal:  Int J Oncol       Date:  1995-03       Impact factor: 5.650

4.  CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

5.  Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.

Authors:  Jan Styczynski; Magdalena Piatkowska; Anna Jaworska-Posadzy; Krzysztof Czyzewski; Malgorzata Kubicka; Beata Kolodziej; Beata Kurylo-Rafinska; Robert Debski; Monika Pogorzala; Mariusz Wysocki
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

6.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  Mutant and wild-type Ras: co-conspirators in cancer.

Authors:  Tikvah K Hayes; Channing J Der
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

8.  Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Andrea Horvat; Bodil Strömbeck; Fredrik Nilsson; Jesper Heldrup; Mikael Behrendtz; Erik Forestier; Anna Andersson; Thoas Fioretos; Bertil Johansson
Journal:  Genes Chromosomes Cancer       Date:  2008-01       Impact factor: 5.006

9.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways.

Authors:  Claire R Weston; Kathryn Balmanno; Claire Chalmers; Kathryn Hadfield; Sarah A Molton; Rebecca Ley; Erwin F Wagner; Simon J Cook
Journal:  Oncogene       Date:  2003-03-06       Impact factor: 9.867
View more
  15 in total

1.  Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.

Authors:  Sydney X Lu; Omar Abdel-Wahab
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

Review 2.  T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.

Authors:  Valentina Cordo'; Jordy C G van der Zwet; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Blood Cancer Discov       Date:  2020-11-24

Review 3.  Clonal evolution in leukemia.

Authors:  Adolfo A Ferrando; Carlos López-Otín
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

4.  Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia.

Authors:  Hong-Hong Zhang; Hong-Sheng Wang; Xiao-Wen Qian; Cui-Qing Fan; Jun Li; Hui Miao; Xiao-Hua Zhu; Yi Yu; Jian-Hua Meng; Ping Cao; Jun Le; Jun-Ye Jiang; Wen-Jing Jiang; Ping Wang; Xiao-Wen Zhai
Journal:  Ann Transl Med       Date:  2019-07

5.  Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia.

Authors:  Steven Goossens; Pieter Van Vlierberghe
Journal:  PLoS Med       Date:  2016-12-20       Impact factor: 11.069

6.  IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.

Authors:  Yunlei Li; Jessica G C A M Buijs-Gladdines; Kirsten Canté-Barrett; Andrew P Stubbs; Eric M Vroegindeweij; Willem K Smits; Ronald van Marion; Winand N M Dinjens; Martin Horstmann; Roland P Kuiper; Rogier C Buijsman; Guido J R Zaman; Peter J van der Spek; Rob Pieters; Jules P P Meijerink
Journal:  PLoS Med       Date:  2016-12-20       Impact factor: 11.069

7.  MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Authors:  Mark Kerstjens; Emma M C Driessen; Merel Willekes; Sandra S Pinhanços; Pauline Schneider; Rob Pieters; Ronald W Stam
Journal:  Oncotarget       Date:  2017-02-28

8.  Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Isabel S Jerchel; Alex Q Hoogkamer; Ingrid M Ariës; Judith M Boer; Nicolle J M Besselink; Marco J Koudijs; Rob Pieters; Monique L den Boer
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

9.  RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  I S Jerchel; A Q Hoogkamer; I M Ariës; E M P Steeghs; J M Boer; N J M Besselink; A Boeree; C van de Ven; H A de Groot-Kruseman; V de Haas; M A Horstmann; G Escherich; C M Zwaan; E Cuppen; M J Koudijs; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2017-10-03       Impact factor: 11.528

10.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Julie A E Irving; Amir Enshaei; Catriona A Parker; Rosemary Sutton; Roland P Kuiper; Amy Erhorn; Lynne Minto; Nicola C Venn; Tamara Law; Jiangyan Yu; Claire Schwab; Rosanna Davies; Elizabeth Matheson; Alysia Davies; Edwin Sonneveld; Monique L den Boer; Sharon B Love; Christine J Harrison; Peter M Hoogerbrugge; Tamas Revesz; Vaskar Saha; Anthony V Moorman
Journal:  Blood       Date:  2016-05-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.